Authentix, Inc. Signs Ten-Year Contract with Botswana Unified Revenue Service to Provide Marketplace Governance Program for Digital Marking and Tracking of Tobacco and Alcohol Products

ADDISON, Texas and GABORONE, Botswana, Aug. 2, 2022 /PRNewswire/ — Authentix announced today it has signed a 10-year contract with the Botswana Unified Revenue Service (BURS) for a fiscal marking and digital tracking solution for tobacco and alcohol products sold in the country.  This digital tax stamp program is aimed at preventing illicit trade and counterfeits while also ensuring that citizens receive genuine and safe products.

The new digital track and trace system will boost tax revenue collections levied on manufacturers and importers by increasing industry compliance, reducing illicit trade, and preventing the underreporting of volumes.  The new contract covers the marking and digital tracking of an estimated 500 million product units per year.

Authentix TransAct™, a secure SaaS-based IT data platform, along with direct printing of secure, serialized digital product codes will combine to form the industry’s leading high security digital tracking and enforcement solution.  The system will reduce and deter fraudulent activities – protecting the public from the harmful effects of contraband and ensuring a level playing field for all legitimate industry stakeholders. The countrywide program will encompass implementation, training, technical support, hardware installation, ongoing maintenance, and program management provided by the Authentix-Botswana Operations Office.

Kevin McKenna, Chief Executive Officer of Authentix, commented “We are delighted that BURS selected and trusted us to implement and manage the country’s first and very important digital tracking solution for these products.  We look forward to working with BURS and implementing the program to help quickly realize the many benefits for the citizens of Botswana.”

Collaborating with governments around the globe, Authentix Marketplace Governance programs have helped ensure the authentication and traceability of products while recovering billions of dollars in tax revenue.

About Authentix:

As the authority in authentication solutions, Authentix thrives in supply chain complexity. Authentix provides advanced authentication solutions for governments, central banks, and commercial products, ensuring local economies grow, banknote security remains intact, and commercial products have greater market opportunities. The Authentix partnership approach and proven sector expertise inspires innovation, helping customers mitigate risks, grow revenue, and gain competitive advantage.  Headquartered in Addison, Texas USA, Authentix, Inc. has offices in the US, UK, Saudi Arabia, Asia, and Africa serving clients worldwide. For more information, visit https://www.authentix.com. Authentix® is a registered trademark of Authentix, Inc.

Logo – https://mma.prnewswire.com/media/429526/Authentix_Logo.jpg

NYI étend ses opérations du 60 Hudson Street

L’acquisition de l’installation Equinix NY8 apporte une capacité de centre de données supplémentaire et un accès rentable à un vaste écosystème d’opérateurs à New York

60 Hudson Street, New York

Centre mondial d’interconnexion

NEW YORK, 02 août 2022 (GLOBE NEWSWIRE) — NYI, l’un des principaux fournisseurs de solutions d’infrastructure hybride et de services gérés, a étendu ses activités du 60 Hudson Street grâce à l’ajout d’espace précédemment occupé par Equinix. Cette expansion est le résultat d’une coentreprise avec QTD Systems, qui a acquis l’espace Equinix dans le cadre d’une transaction conclue le 1er août 2022.

Grâce à cette intégration, NYI double son nombre de centres de données et élargit immédiatement l’écosystème des opérateurs mis à la disposition des clients. L’expansion inclut également une infrastructure de conduit supplémentaire significative et un accès à l’alimentation électrique par Ethernet (PoE), qui fourniront une capacité et une portée inégalées dans l’immeuble le plus connecté de New York. Avec les capacités déjà présentes dans l’immeuble de NYI, les clients auront désormais accès à des niveaux de résilience inégalés lorsqu’ils déploieront leur stratégie d’interconnexion.

« Avec l’accélération de la transformation numérique, le rôle de 60 Hudson Street en tant que lieu prééminent pour les opérateurs mondiaux de la ville de New York devient inestimable. Il permettra de satisfaire les besoins croissants en matière de connectivité des clients », a déclaré Phillip Koblence, cofondateur et directeur des opérations de NYI. « Grâce à cette intégration, NYI augmente sa capacité à servir d’intermédiaire de premier plan pour l’accès à cette passerelle d’interconnexion mondiale, tout en rendant les déploiements à 60 Hudson Street plus simples et plus rentables. »

« J’ai une longue carrière chez 60 Hudson Street, où j’ai créé au cours des vingt dernières années plusieurs entreprises de centres de données et de connectivité qui sont toujours opérationnelles. Je me réjouis de voir NYI continuer à fournir des services de qualité et à s’appuyer sur l’infrastructure 60 Hudson NY8 d’Equinix pour booster l’avenir de l’interconnexion », a ajouté Peter Feldman, PDG de QTD Systems.

L’expansion bénéficiera à plusieurs parties :

  • Les anciens clients d’Equinix profiteront d’une continuité opérationnelle et d’un accès au personnel technique expert sur site de NYI, à la plateforme d’interconnexion rentable et à la suite de solutions d’infrastructure hybrides et de services gérés interactifs.
  • Les clients nationaux et internationaux auront accès à davantage d’espace et d’énergie, ainsi qu’à un écosystème d’opérateurs élargi.
  • Les fournisseurs et opérateurs de télécommunications bénéficieront d’un accès transparent et rentable à l’infrastructure étendue de conduit dans l’immeuble de NYI et à d’autres points d’entrée.

Grâce à des capacités étendues et à un engagement continu à réduire la complexité et à fournir une expérience client fluide, NYI espère proposer une situation équitable, rendant l’interconnexion à 60 Hudson Street plus simple et plus accessible du point de vue du déploiement et des coûts, pour les opérateurs, les fournisseurs de contenu et les entreprises de toutes tailles.

À propos de NYI

NYI est un fournisseur de premier plan de solutions hybrides d’infrastructure, de réseau et d’interconnexion. La société est connue pour réduire la complexité du paysage informatique et faciliter les solutions personnalisées afin de répondre aux besoins critiques des clients de tous les secteurs en matière d’infrastructure et de connectivité. NYI a son siège social à New York et fournit des services d’entreprise sur des marchés mondiaux clés grâce à un écosystème de partenaires de confiance. Pour en savoir plus sur NYI, rendez-vous sur nyi.net ou suivez NYI sur Twitter ou LinkedIn.

Contact auprès des médias :
Iromie Weeramantry, vice-président du Marketing
marketing@nyi.net

À propos de QTD Systems

Peter Feldman, PDG de QTD Systems, possède plus de 25 ans d’expérience dans le développement, les opérations, la gestion et la conception de centres de données, y compris la création de deux entreprises de longue date à 60 Hudson Street à New York, à savoir Telx (maintenant Digital Realty Trust) et DataGryd (maintenant Hudson IX). Il a également cofondé Digital Crossroads à Hammond, dans l’Indiana. QTD Systems se concentrera sur le développement de la prochaine génération de technologies Quantum en partenariat avec Novum Industria, une société dérivée, ou spinoff, du MIT et membre de Quantum Economic Development Corp (QED-C) dans l’ancienne installation de NY8.

Une photo accompagnant cette annonce est disponible à l’adresse https://www.globenewswire.com/NewsRoom/AttachmentNg/0cab232c-0c8d-4915-9d67-15f658bcef3b/fr

The Rockefeller Foundation Launches the Vaccination Action Network to Strengthen Health Systems and Scale Up Covid-19 Vaccinations in sub-Saharan Africa

Amref Health Africa selected as implementing partner to provide technical assistance for the new peer-to-peer learning network

NAIROBI, Kenya, August 2, 2022 /PRNewswire/ — The Rockefeller Foundation announces the launch of the Vaccination Action Network (VAN), a USD$7.4 million locally-led, peer-to-peer learning initiative designed to engage public health decision-makers across sub-Saharan Africa and bolster their efforts to strengthen health systems while scaling up Covid-19 vaccine demand strategies. Sabin Vaccine Institute and Dalberg are the secretariat for the network, while Amref Health Africa (Amref) is playing a key role to guide and administer subgrants to local organizations in participating countries so that they can implement vaccine demand generation strategies discussed during the learning sessions.

The network is already connecting ministry of health officials, implementing partners, and other key actors across Kenya, Malawi, Tanzania, and Uganda through activities designed to take place within and between countries (intra- and cross-country), so participants can share lessons learned and best practices for boosting local demand for Covid-19 vaccines. Plans to expand to other countries in the region are underway as well.

“The Vaccination Action Network’s community-based approach brings together our counterparts from across the region and country. This collaboration is the key to finding and implementing the right vaccination approach,” said Dr. Diana Atwine, Permanent Secretary, Ministry of Health, Uganda. In a recent VAN learning session focused on Wakiso district, Dr. Mathias Lugoloobi, District Health Officer in Uganda’s central Wakiso District echoed this sentiment, saying that “for strategies to be successful, the community alone must have the final say.”

While more than 60 percent of people have been fully vaccinated against Covid-19 globally, just 20 percent of people in Africa have received full doses. Inconsistent and inequitable access to supplies initially hindered the continent’s vaccination campaigns. However, uptake is now primarily impacted by complex delivery scenarios, limited access to vaccination centers, and other ongoing demand barriers, such as vaccine hesitancy and waning concerns about Covid-19 infection.

VAN’s objective is to help decision-makers understand the drivers behind vaccination and support initiatives that will increase Covid-19 vaccine uptake, while strengthening routine immunization so that health systems are better equipped to respond when the next pandemic strikes. This reflects The Rockefeller Foundation’s regional commitment to support localized solutions, empower community representatives, and create more resilient health systems.

“The Vaccination Action Network is helping to establish new channels of communication that will consistently elevate regional learnings, solutions, and leadership,” said William Asiko, Vice President of The Rockefeller Foundation Africa Regional Office. “By making these discussions country-led, we want to create a space where those directly involved in vaccination campaigns are able to voice what is working, what isn’t, and what needs to change to improve vaccination rates.”

Peer-to-peer learning is an important tool for officials who are working to address these challenges. Since the start of the Covid-19 pandemic, this type of intra- and inter-country coordination has helped the continent scale up genomic sequencing and secure essential tools, including personal protective equipment and diagnostic tests.

“By encouraging officials to come together, the Vaccination Action Network is opening new dialogues that emphasize regional solutions to local challenges,” said Githinji Gitahi, Group CEO at Amref. “This is essential to tackle vaccine equity issues, which are tied to national and regional contexts, but also offers countries an opportunity for longer-term coordination on other priorities.”

VAN will host monthly intra-country sessions and multiple cross-country discussions before the end of the calendar year, with the goal of turning learnings from these sessions into actionable solutions. To facilitate this, VAN is supporting Amref through a USD$5 million grant to design and implement tailored strategies that better reflect local needs and address demand barriers for increased vaccine uptake.

Prior to the launch, VAN hosted two cross-country and five intra-country discussions, which have already yielded results. Following a May VAN session focused on improving vaccine understanding and uptake, the Infectious Diseases Institute (IDI) at Makerere University in Kampala, Uganda is now working to train “vaccination champions” in the Wakiso district. The goal is for champions to connect with communities about the benefits of vaccines, address their questions and concerns, and ultimately encourage vaccination through community-based strategies that have proved successful in past epidemic control settings in Uganda.

“One of our biggest takeaways from the VAN conversation was that we needed to do more to engage communities with accurate and approachable information on Covid-19 vaccines, leaning on lessons learned from other health challenges such as HIV and Ebola,” said Mohammed Lamorde, Head of Global Health Security at IDI. “That’s why our program focuses on working with trusted community members and leaders to equip them with the tools they need to encourage greater uptake of vaccines within their communities.”

VAN represents the Global Vaccination Initiative (GVI)’s first major investment in overcoming low vaccine demand in Africa. Launched in April 2022, GVI is The Rockefeller Foundation’s USD$55 million effort to support country-led efforts to fully vaccinate 90% of the most at-risk populations in Africa, Asia, Latin America, and the Caribbean over the next two years.

About The Rockefeller Foundation

The Rockefeller Foundation is a pioneering philanthropy built on collaborative partnerships at the frontiers of science, technology, and innovation to enable individuals, families, and communities to flourish. We work to promote the well-being of humanity and make opportunity universal.  Our focus is on scaling renewable energy for all, stimulating economic mobility, and ensuring equitable access to healthy and nutritious food.  For more information, sign up for our newsletter at rockefellerfoundation.org and follow us on Twitter @RockefellerFdn.

Amref Health Africa, headquartered in Kenya, is the largest Africa-based International Non-Governmental Organisation (INGO). With a focus on increasing sustainable health access, Amref runs programmes in over 35 countries in Africa, with lessons learnt over 60 years of engagement with governments, communities, and partners. Amref Health Africa also engages in programme development, fundraising, partnership, advocacy, monitoring and evaluation, and has offices in Europe and North America as well as subsidiaries: Amref Flying Doctors, Amref Enterprises and the Amref International University.

About Dalberg

Dalberg is a leading social impact advisory group that brings together strategy consulting, design thinking, big data analytics, and research to address complex social and environmental challenges. It works collaboratively with communities, institutions, governments, and corporations to develop solutions that create impact at scale. The Dalberg Group is comprised of six businesses: Dalberg Advisors, Dalberg Data Insights, Dalberg Design, Dalberg Implement, Dalberg Media, and Dalberg Research, and a not-for-profit, Dalberg Catalyst. For more information, visit www.dalberg.com.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

AOP Health Starts Research for Leukemia Treatment

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.

Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group

Photo credit: Studio Koekart: Natascha Unkart & Isabelle Köhler

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.

Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech

Copyright: Albert Mollon

Agreement sets basis for new areas of therapy

At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”

Development in cooperation with Leukos

As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.

About Leukos

Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.

About the Josep Carreras Foundation

The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.

About the Josep Carreras Leukaemia Research Institute

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus

About Inveready

Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Needs. Science. Trust.

AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

AOP Health commence la recherche d’un traitement pour la leucémie

AOP Health a signé un accord avec Leukos Biotech pour la poursuite du développement d’une substance chimique récemment découverte. Avec cet accord, AOP Health élargit encore davantage le domaine de la recherche sur l’hémato-oncologie et propose des options de traitement supplémentaires à certains patients atteints de leucémie sur le long terme.

VIENNE, Autriche, 01 août 2022 (GLOBE NEWSWIRE) — AOP Health Group (AOP Health) est un pionnier européen des thérapies intégrées pour les maladies rares et les soins intensifs basé à Vienne, en Autriche. La société se concentre sur la recherche, le développement et la vente mondiale de solutions de traitement innovantes et se spécialise dans les thérapies pour les maladies rares et les soins intensifs. Début juillet, AOP Health a signé un accord avec Leukos Biotech, une société dérivée fondée par l’institut de recherche sur la leucémie Josep Carreras, basé à Barcelone. L’accord signé par AOP Health couvre l’option de développement de la substance chimique récemment découverte dans le cadre de toute indication traitable, non limitée aux maladies oncologiques ou rares.

L’accord établit la base de nouveaux domaines thérapeutiques

Dans un premier temps, AOP Health se concentrera sur le développement d’options de traitement pour la leucémie myéloïde aiguë (LMA) et le syndrome myélodysplasique (SMD). Les deux sont des types particuliers de leucémie qui commencent souvent dans la moelle osseuse. Agnes Kohl, directrice commerciale d’AOP Orphan Pharmaceuticals GmbH, membre du groupe AOP Health, explique : « Sur la base de données positives, notre plan est d’étendre le développement d’autres indications orphelines même en dehors de la LMA et du SMD à un stade ultérieur. Grâce à cet accord, nous pourrons peut-être élargir le portefeuille de nos domaines thérapeutiques en offrant encore plus d’options de traitement aux patients. »

Développement en coopération avec Leukos

Comme AOP Health se concentre sur les cancers hémato-oncologiques rares et possède de nombreuses années d’expérience dans le développement et la commercialisation de traitements hémato-oncologiques, la société pilotera le développement ultérieur de la substance en coopération avec Leukos sur la base d’un nouveau mode d’action. Cela pourrait potentiellement devenir une étape importante dans le traitement de nombreux cancers du sang et autres patients atteints de cancer. Luis Ruiz-Avila, PDG de Leukos Biotech : « Nous nous concentrons sur le développement de nouveaux traitements pour une grande variété de tumeurs. Nous sommes nés pour transformer l’excellente science de l’Institut de recherche sur la leucémie Josep Carreras en produits précieux pour les patients atteints de cancer dans le besoin, et cet accord est une étape très importante dans cette direction. Nous sommes convaincus qu’AOP Health est le bon partenaire pour transformer ce nouveau mécanisme d’action prometteur en une réalité clinique au profit des patients présentant une grande variété de besoins médicaux non satisfaits. »

À propos d’AOP Health

Le groupe AOP Health comprend plusieurs sociétés, dont AOP Orphan Pharmaceuticals GmbH, dont le siège se trouve à Vienne, en Autriche (« AOP Health »). Le groupe AOP Health est le pionnier européen des thérapies intégrées pour les maladies rares et les soins critiques. Au cours des 25 dernières années, le groupe est devenu un fournisseur établi de solutions de thérapie intégrées opérant depuis son siège social à Vienne, ses filiales et ses bureaux de représentation à travers l’Europe et le Moyen-Orient, ainsi que par l’intermédiaire de partenaires dans le monde entier. Ce développement a été rendu possible par un niveau d’investissement continu élevé dans la recherche et le développement, d’une part, et par une orientation très cohérente et pragmatique vis-à-vis des besoins de toutes ses parties prenantes, d’autre part, en particulier les patients et leurs familles, ainsi que les professionnels de la santé qui les prennent en charge.

À propos de Leukos

Leukos Biotech, SL (Leukos) est une société dérivée de l’Institut de recherche sur la leucémie Josep Carreras, créée à Barcelone en 2015. La société développe de nouveaux traitements et outils de diagnostic pour une large variété de tumeurs ciblant le récepteur de la sérotonine HTR1B, dont le potentiel antitumoral a été décrit pour la première fois et breveté par le Dr Ruth Risueño, fondateur de Leukos dans son laboratoire à l’Institut de recherche Josep Carreras. Le principal soutien financier de Leukos provient d’investisseurs privés et institutionnels. Les principaux actionnaires sont Inveready, CDTI Innvierte et la Fondation Josep Carreras. Outre le soutien des investisseurs, Leukos a reçu des subventions et des prêts non dilutifs du gouvernement catalan, du gouvernement espagnol et de l’Union européenne dans le cadre de divers programmes.

À propos de la Fondation Josep Carreras

La Fondation Josep Carreras Leukaemia a été créée en 1988 dans le but de contribuer à la recherche d’un remède définitif pour cette maladie. Ses efforts se concentrent sur quatre domaines fondamentaux : l’administration du Registre espagnol de donneurs de moelle osseuse (REDMO), la recherche scientifique menée par l’Institut de recherche sur la leucémie Josep Carreras, l’orientation des patients via un canal de consultation des patients en ligne et des appartements d’accueil pour les patients qui ont besoin de subir un traitement et doivent passer beaucoup de temps loin de chez eux.

À propos de l’Institut de recherche sur la leucémie Josep Carreras

L’Institut de recherche sur la leucémie Josep Carreras, centre public appartenant au réseau CERCA de la Generalitat de Catalunya, a été créé en 2010 dans le but de promouvoir la recherche biomédicale et la médecine personnalisée dans le domaine de la leucémie et d’autres maladies onco-hématologiques. Il s’agit du premier centre de recherche européen exclusivement dédié à la leucémie et aux hémopathies malignes, et l’un des rares au monde. Les Instituts Josep Carreras disposent de trois campus scientifiques coordonnés mais indépendants : le Campus clinique de l’Hôpital de l’Université de Barcelone, le Campus de l’Institut catalan d’oncologie/allemands Trias i Pujol et le Campus de Sant Pau – Autonomous University of Barcelona (UAB).

À propos d’Inveready

Inveready est un gestionnaire d’actifs alternatifs de premier plan en Espagne ; il investit dans le capital-risque en phase de démarrage, le capital-risque de croissance, la dette à risque, les actions stratégiques dans des sociétés cotées, les infrastructures et le capital-investissement privé. Il fournit des solutions de financement aux entreprises tout au long de leur cycle de vie. Fondée en 2008, Inveready compte sur 200 sociétés actives et plus d’un milliard d’euros d’actifs sous gestion. Inveready investit dans des entreprises du secteur des sciences de la vie depuis 2008. Les investissements notables dans ce secteur sont Atrys Health (cotée sur le marché espagnol), EDESA Biotech (cotée au Nasdaq), AVX Pharma (vendue à Aerie Biotech) et PaloBiofarma (accord de licence avec Novartis). Le siège social de la société se situe à San Sebastian et elle possède d’autres bureaux à Barcelone et Madrid. La société a été reconnue à plusieurs reprises par l’ASCRI et Preqin pour le rendement de ses fonds et de ses transactions (Pour plus d’informations, veuillez consulter le site www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Besoins. Science. Confiance.

AOP Orphan Pharmaceuticals GmbH
Membre du groupe AOP Health

Leopold-Ungar-Platz 2, 1190 Vienne, Autriche
aop-health.com

Des photographies accompagnant ce communiqué sont disponibles aux adresses :

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease  

WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). The main objective of the Phase 1/2 is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

TED is a debilitating vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. With no approved therapies for TED patients in China, treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) intended for the treatment of TED.

“We are proud that the IND application for ZB001 was approved by the NMPA about two months following its submission, highlighting our team’s unique ability to efficiently execute on our development programs,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “We are excited to work with leading clinical experts in China to accelerate the development of ZB001 to address the significant unmet clinical need in thyroid eye disease.”

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics, Inc. (Viridian) in October 2020. After submitting an IND for VRDN-001 to the U.S. Food and Drug Administration in October 2021, Viridian initiated a Phase 1/2 clinical trial in December 2021 to evaluate proof of concept in TED patients in North America and released encouraging interim healthy volunteer data suggesting robust activity with excellent safety and tolerability of the candidate product.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com